The number of patients presenting with Peyronie's disease (PD) appears to be on the rise.
This review provides an analysis of pertinent recent updates in the management of PD, focusing on data published within the past year. Objective benefit from injectable agents has been reported for years in mostly noncontrolled trials. The safety and efficacy of injectable collagenase clostridium histolyticum is now supported by data from a large-scale phase III randomized controlled trial. Other important advances have also been made in the surgical management of Peyronie's disease, including new modifications to proven surgical techniques and a variety of approaches that can help enhance and restore penile length.
Sherer BA, Warrior K, Levine LA. Are you the author?
Rush University Medical Center, Suite 348, 1725 Harrison St, Chicago, IL, 60612, USA.
Reference: Curr Urol Rep. 2014 Dec;15(12):459.